Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review

The increase in obesity and the aging of the population has lead to an increase in the incidence of type 2 diabetes. This has led to the development of new drugs such as thiazolidinediones (TZDs) which are Peroxisome Proliferator-Activated Receptor (PPARgamma) agonists, to treat type 2 diabetes. TZD...

Descripción completa

Detalles Bibliográficos
Autores principales: Desouza, Cyrus V., Shivaswamy, Vijay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411525/
https://www.ncbi.nlm.nih.gov/pubmed/22879786
_version_ 1782239842079342592
author Desouza, Cyrus V.
Shivaswamy, Vijay
author_facet Desouza, Cyrus V.
Shivaswamy, Vijay
author_sort Desouza, Cyrus V.
collection PubMed
description The increase in obesity and the aging of the population has lead to an increase in the incidence of type 2 diabetes. This has led to the development of new drugs such as thiazolidinediones (TZDs) which are Peroxisome Proliferator-Activated Receptor (PPARgamma) agonists, to treat type 2 diabetes. TZDs have recently been at the center of a controversy with regards to their cardiovascular safety. Pioglitazone is a TZD which has been shown to be effective in glycemic control by lowering insulin resistance. Pioglitazone also has beneficial effects on lipid metabolism and cardiovascular risk. The safety and efficacy of pioglitazone including its pleotropic effects are discussed at length in this article.
format Online
Article
Text
id pubmed-3411525
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-34115252012-08-09 Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review Desouza, Cyrus V. Shivaswamy, Vijay Clin Med Insights Endocrinol Diabetes Review The increase in obesity and the aging of the population has lead to an increase in the incidence of type 2 diabetes. This has led to the development of new drugs such as thiazolidinediones (TZDs) which are Peroxisome Proliferator-Activated Receptor (PPARgamma) agonists, to treat type 2 diabetes. TZDs have recently been at the center of a controversy with regards to their cardiovascular safety. Pioglitazone is a TZD which has been shown to be effective in glycemic control by lowering insulin resistance. Pioglitazone also has beneficial effects on lipid metabolism and cardiovascular risk. The safety and efficacy of pioglitazone including its pleotropic effects are discussed at length in this article. Libertas Academica 2010-08-03 /pmc/articles/PMC3411525/ /pubmed/22879786 Text en © the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
spellingShingle Review
Desouza, Cyrus V.
Shivaswamy, Vijay
Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review
title Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review
title_full Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review
title_fullStr Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review
title_full_unstemmed Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review
title_short Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review
title_sort pioglitazone in the treatment of type 2 diabetes: safety and efficacy review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411525/
https://www.ncbi.nlm.nih.gov/pubmed/22879786
work_keys_str_mv AT desouzacyrusv pioglitazoneinthetreatmentoftype2diabetessafetyandefficacyreview
AT shivaswamyvijay pioglitazoneinthetreatmentoftype2diabetessafetyandefficacyreview

Ejemplares similares